Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.

Ina Kötter; Manfred Zierhut; Anja Eckstein; Reinhard Vonthein; Thomas Ness; Ilhan Günaydin; Bodo Grimbacher; Sabine Blaschke; Hans Hartmut Peter; Lothar Kanz; Nicole Stübiger

Journal Article

Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.

Kötter I
Zierhut M
Eckstein A
et al.

Advances in experimental medicine and biology (2003) 528 521-523

DOI: 10.1007/0-306-48382-3_104

26Citations

9Readers

Get full text

Cite

CITATION STYLE

APA

Kötter, I., Zierhut, M., Eckstein, A., Vonthein, R., Ness, T., Günaydin, I., … Stübiger, N. (2003). Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet’s disease with sight-threatening retinal vasculitis. Advances in Experimental Medicine and Biology, 528, 521–523. https://doi.org/10.1007/0-306-48382-3_104

Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.

Cite

Register to see more suggestions